Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy.
Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy.
复制标题
DOI：
10.4111/kju.2012.53.9.593
复制
发表时间：
2012-09
期刊：
影响因子：
--
通讯作者：
Kim DS
中科院分区：
文献类型：
--
作者：
Jeon KP;Jeong TY;Lee SY;Hwang SW;Shin JH;Kim DS
代谢综合征（MS）与前列腺癌关系的研究一直存在争议。我们评估了接受经直肠超声引导前列腺活检的患者中多发性硬化症与前列腺癌特征之间的关系。2003年10月至2011年5月，前列腺特异性抗原（PSA）值≥4 ng/ml或直肠指检（DRE）结果异常的患者行经直肠超声引导前列腺活检。根据成人治疗组III诊断多发性硬化症。临床病理因素包括PSA、DRE、前列腺体积、年龄、腰围、体重指数（BMI）、脂质谱、空腹血糖水平和MS。354例患者入组，平均年龄68.86±8.95岁，平均PSA为13.97±20.42 ng/ml。75例（21.2%）患者患有多发性硬化症，90例（25.4%）患者被诊断患有前列腺癌，其中27例（30%）患有多发性硬化症，63例（70%）未患有多发性硬化症。总PSA值和前列腺体积是前列腺癌的重要预测因子。然而，多发性硬化症和身体质量指数与癌症风险的增加没有显著相关。前列腺癌多发性硬化患者的Gleason评分（平均6.63±1.92）明显低于非多发性硬化患者（平均7.54±1.71;p=0.029）。多发性硬化症的存在与高级别前列腺癌的风险显著降低相关。一个更大的，前瞻性的，多中心的研究是必要的，以阐明多发性硬化症和前列腺癌之间的关系。
Studies on the relationship of metabolic syndrome (MS) and prostate cancer are controversial. We evaluated the association between MS and prostate cancer characteristics in patients who underwent transrectal ultrasound-guided prostate biopsy. From October 2003 to May 2011, patients with a prostate-specific antigen (PSA) value≥4 ng/ml or abnormal digital rectal examination (DRE) result underwent transrectal ultrasound-guided prostate biopsy. MS was diagnosed according to the Adult Treatment Panel III. Clinicopathologic factors including PSA, DRE, prostate volume, age, waist circumference, body mass index (BMI), lipid profiles, fasting blood sugar level, and MS were considered for analysis. Three hundred fifty-four patients were enrolled (mean age, 68.86±8.95 years; mean PSA, 13.97±20.42 ng/ml). Seventy-five patients (21.2%) had MS and 90 patients (25.4%) were diagnosed as having prostate cancer, including 27 (30%) with MS and 63 (70%) without MS. Total PSA value and prostate volume were significant predictors for prostate cancer. However, MS and BMI were not significantly related to increased cancer risk. Prostate cancer patients with MS had significantly lower Gleason scores (average, 6.63±1.92) than did prostate cancer patients without MS (average, 7.54±1.71; p=0.029). Presence of MS was associated with a significantly decreased risk of high-grade prostate cancer. A larger, prospective, multicenter investigation is mandatory to clarify the relationship between MS and prostate cancer.